Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma

NCT02418988 is registered in ClinicalTrials.gov with Shenzhen SiBiono GeneTech Co.,Ltd as lead sponsor.

NCT NCT02418988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02418988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
Lead sponsor
Shenzhen SiBiono GeneTech Co.,Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2014
Completion date
December 31, 2017
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma